Exemestane CAS 107868-30-4 Anti Estrogen Steroids Aromasin Powder
for Breast Cancer Treatment
Appearance:White or Almost White Crystalline Powder
|Product Categories:||Active Pharmaceutical Ingredients;chiral;Antineoplastic
(Hormonal);Intermediates & Fine
Chemicals;Pharmaceuticals;Steroids;Pfizer compounds;Steroid and
Developed to help fight breast cancer, Aromasin is one of the most
powerful estrogen suppressing compounds.
Exemestane is an oral steroidal aromatase inhibitor that is used in
ER-positive breast cancer in addition to surgery and/or radiation
in post-menopausal women.
The main source of estrogen is the ovaries in premenopausal women,
while in post-menopausal women most of the body's estrogen is
produced via the conversion of androgens into estrogen by the
aromatase enzyme in the peripheral tissues (i.e. adipose tissue
like that of the breast) and a number of sites in the brain.
Estrogen is produced locally via the actions of the aromatase
enzyme in these peripheral tissues where it acts locally. Any
circulating estrogen in post-menopausal women as well as men is the
result of estrogen escaping local metabolism and entering the
Exemestane is an irreversible, steroidal aromatase inactivator,
structurally related to the natural substrate androstenedione. It
acts as a false substrate for the aromatase enzyme, and is
processed to an intermediate that binds irreversibly to the active
site of the enzyme causing its inactivation, an effect also known
as "suicide inhibition." By being structurally similar to enzyme
targets, Exemestane permanently binds to the enzymes, preventing
them from converting androgen into estrogen.
Exemestane is taken in tablet form once a day. Patients can
experience side effects like nausea, anxiety, shortness of breath,
abdominal pain, bone pain, and chest pain. Side effects vary widely
between patients and patients should report the side effects they
experience to their doctors, as some may be indicators of dangerous
complications. Shortness of breath and chest pain in particular are
causes for concern in patients taking exemestane.
For early and advanced breast cancer:
Recommended dose: 25 mg orally once daily after a meal.